G
Giuliano Becker
Researcher at Université de Montréal
Publications - 23
Citations - 513
Giuliano Becker is an academic researcher from Université de Montréal. The author has contributed to research in topics: Medicine & Catheter ablation. The author has an hindex of 9, co-authored 21 publications receiving 334 citations. Previous affiliations of Giuliano Becker include McGill University.
Papers
More filters
Journal ArticleDOI
Prevention of Arrhythmia Device Infection Trial: The PADIT Trial.
Andrew D. Krahn,Yves Longtin,François Philippon,David H. Birnie,Jaimie Manlucu,Paul Angaran,Claus Rinne,Benoit Coutu,R. Aaron Low,Vidal Essebag,Carlos A. Morillo,Damian P. Redfearn,Satish Toal,Giuliano Becker,Michel Degrâce,Bernard Thibault,Eugene Crystal,Stanley Tung,John LeMaitre,Omar Sultan,Matthew T. Bennett,Jamil Bashir,Felix Ayala-Paredes,Philippe Gervais,Leon Rioux,Martin E.W. Hemels,Leon H.R. Bouwels,Bob van Vlies,Jia Wang,Derek V. Exner,Paul Dorian,Ratika Parkash,Marco Alings,Stuart J. Connolly +33 more
TL;DR: The cluster crossover design efficiently tested clinical effectiveness of incremental antibiotics to reduce device infection and the observed difference in infection rates was not statistically significant.
Journal ArticleDOI
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
David H. Birnie,Jeff S. Healey,George A. Wells,Felix Ayala-Paredes,Benoit Coutu,Glen L. Sumner,Giuliano Becker,Atul Verma,François Philippon,Eli Kalfon,John W. Eikelboom,Roopinder K. Sandhu,Pablo B. Nery,Nicholas Lellouche,Stuart J. Connolly,John L. Sapp,Vidal Essebag +16 more
TL;DR: The results suggest that, dependent on the clinical scenario, either management strategy (continued DOAC or interrupted DOAC) might be reasonable, at least for patients similar to those enrolled in the trial.
Journal ArticleDOI
Risk Factors for Infections Involving Cardiac Implanted Electronic Devices.
David H. Birnie,Jia Wang,Marco Alings,François Philippon,Ratika Parkash,Jaimie Manlucu,Paul Angaran,Claus Rinne,Benoit Coutu,R. Aaron Low,Vidal Essebag,Carlos A. Morillo,Damian P. Redfearn,Satish Toal,Giuliano Becker,Michel Degrâce,Bernard Thibault,Eugene Crystal,Stanley Tung,John LeMaitre,Omar Sultan,Matthew T. Bennett,Jamil Bashir,Felix Ayala-Paredes,Philippe Gervais,Leon Rioux,Martin E.W. Hemels,Leon H.R. Bouwels,Derek V. Exner,Paul Dorian,Stuart J. Connolly,Yves Longtin,Andrew D. Krahn +32 more
TL;DR: This study identified 5 independent predictors of device infection and developed a novel infection risk score in the largest cardiac implantable electronic device trial to date, warranting validation in an independent cohort.
Journal ArticleDOI
Anticoagulation Management Pre- and Post Atrial Fibrillation Ablation: A Survey of Canadian Centres
Vartan Mardigyan,Atul Verma,David H. Birnie,Peter G. Guerra,Damian P. Redfearn,Giuliano Becker,Jean Champagne,John L. Sapp,Lorne J. Gula,Ratika Parkash,Laurent Macle,Eugene Crystal,Gilles O'Hara,Yaariv Khaykin,M. Sturmer,George D. Veenhuyzen,Isabelle Greiss,Jean-François Sarrazin,Iqwal Mangat,Paul Novak,Allan C. Skanes,Jean-Francois Roux,Vijay S. Chauhan,Tom Hadjis,Carlos A. Morillo,Vidal Essebag +25 more
TL;DR: Although guidelines recommend long-term anticoagulation in patients with CHADS(2) ≥ 2, 11% of physicians would discontinue warfarin in Patients with no evidence of recurrent AF 1 year post successful ablation, according to the purpose of this study.
Clinical Research Anticoagulation Management Pre- and Post Atrial Fibrillation Ablation: A Survey of Canadian Centres
Vartan Mardigyan,Atul Verma,David Birnie,Peter G. Guerra,Damian P. Redfearn,Giuliano Becker,Jean Champagne,John L. Sapp,Lorne J. Gula,Ratika Parkash,Laurent Macle,Eugene Crystal,Yaariv Khaykin,Marcio Sturmer,George D. Veenhuyzen,Isabelle Greiss,Jean-Francois Sarrazin,Iqwal Mangat,Paul Novak,Allan C. Skanes,Jean-Francois Roux,V.B.S. Chauhan,Tom Hadjis,Carlos A. Morillo,Vidal Essebag +24 more
TL;DR: In this article, a broad range of approaches to anticoagulation management pre and post atrial fibrillation (AF) ablation procedures are presented. But, the authors focus on the pre-and post-AF ablation.